Bibliography
- Ohayon M. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002;6:97-111
- Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008;4(5):487-504
- National Sleep Foundation. 2005 sleep in America poll. Washington, D.C.: National Sleep Foundation; 2005
- Buysse DJ, Angst J, Gamma A, et al. Prevalence, course, and comorbidity of insomnia and depression in young adults. Sleep 2008;31(4):473-80
- Parish JM. Sleep-related problems in common medical conditions. Chest 2009;135(2):563-7
- Stewart R, Besset A, Bebbington P, et al. Insomnia comorbidity and impact and hypnotic use by age group in a national survey population aged 16 to 74 years. Sleep 2006;29(11):1391-7
- Sateia MJ, Doghramji K, Hauri PJ, Morin CM. Evaluation of chronic insomnia: an American Academy of Sleep Medicine review. Sleep 2000;23:243-308
- American academy of sleep medicine. International classification of sleep disorders, 2nd edition: diagnostic and coding manual. Westchester, IL: American academy of sleep medicine, 2005
- Jansson-Fröjmark M, Linton SJ. The course of insomnia over one year: a longitudinal study in the general population in sweden. Sleep 2008;31(6):881-6
- Neubauer D. Current and new thinking in the management fo comorbid insomnia. Am J Manag Care 2009;15(1):S24-32
- Terzano MG, Parrino L, Spaggiari MC, et al. CAP variables and arousals as sleep electroencephalogram markers for primary insomnia. Clin Neurophysiol 2003;114:1715-23
- Edinger JD, Means MK, Carney CE, Krystal AD. Psychomotor performance deficits and their relation to prior nights' sleep among individuals with primary insomnia. Sleep 2008;31(5):599-607
- Daley M, Morin CM, LeBlanc M, et al. The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers. Sleep 2009;32(1):55-64
- Sipkoff M. Successful treatment of insomnia starts with formulary design. Manag Care 2006;15(11). Available from: http://www.managedcaremag.com/ archives/0611/0611.medmgmt.html
- Manifestations and management of chronic insomnia in adults. NIH State-of-the-Science Conference Statement 2005. Available from: http://consensus.nih.gov/2005/ 2005InsomniaSOS026html.htm
- Available from: www.hypnion.com/programs/sleepfacts.htm. [Accessed 25 May 2009]
- O'Brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry 2005;66(Suppl 2):28-33
- Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 2004;18(1):37-48
- Ozminkowski RJ, Wang S, Walsh JK. The direct a nd indirect costs of untreated insomnia in adults in the United States. Sleep 2007;30:263-73
- Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Int Med 2007;22(9):1335-50
- Montplaisir J, Hawa R, Moller H, et al. Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement. Hum Psychopharmacol 2003;18(1):29-38
- Borja NL, Daniel KL. Ramelteon for the treatment of insomnia. Clin Ther 2006;28(10):1540-55
- Wafford K, Ebert B. Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time. Nat Rev Drug Discov 2008;7(6):530-40
- Vermeeren A. Residual effects of hypnotics. CNS Drugs 2004;18:297-328
- Hajak G, Müller WE, Wittchen HU, et al. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone a review of case reports and epidemiological data. Addiction 2003;98:1371-8
- Mendelson W. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005;66(4):469-76
- Scharf M, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1mg, 3mg, and 6mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2008;69:1557-64
- Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007;30(8):959-68
- Roth T, Walsh JK, Krystal A, et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005;6(6):487-95
- Ancoli-Israel S, Richardson GS, Mangano RM, et al. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med 2005;6(2):107-13
- Krystal AD, Erman M, Zammit GK, et al.; ZOLONG Study Group. Long term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, doubleblind, placebo-controlled, parallel-group, multicenter study. Sleep 2008;31(1):79-90
- Edinger JD, Olsen MK, Stechuchak KM, et al. Cognitive behavioral therapy for patients with primary insomnia or insomnia associated predominantly with mixed psychiatric disorders: a randomized clinical trial. Sleep 2009;32(4):499-510
- Manber R, Edinger JD, Gress JL, et al. Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. Sleep 2008;31(4):489-95
- Morin CM, Bootzin RR, Buysse DJ, et al. Psychological and behavioral treatment of insomnia: update of the recent evidence (1998-2004). Sleep 2006;29(11):1398-414
- Sivertsen B, Omvik S, Pallesen S, et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA 2006;295(24):2851-8
- Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005;437(7063):1257-63
- Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW. Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Arch Intern Med 2004;164(17):1888-96
- Leufkens TR, Lund JS, Vermeeren A. Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem. J Sleep Res 2009 [Epub ahead of print]
- Otmani S, Demazières A, Staner C, et al. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol 2008;23(8):693-705
- Fava M, Asnis GM, Shrivastava R, et al. Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. J Clin Psychopharmacol 2009;29(3):222-30
- Pollack M, Kinrys G, Krystal A, et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry 2008;65(5):551-62
- Fava M, McCall WV, Krystal A, et al. Eszopiclone coadministered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006;59(11):1052-60
- Krystal A, Fava M, Rubens R, et al. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. J Clin Sleep Med 2007;3(1):48-55
- Asnis GM, Chakraburtty A, DuBoff EA, et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 1999;60(10):668-76
- Soares CN, Joffe H, Rubens R, et al. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol 2006;108(6):1402-10
- Dorsey CM, Lee KA, Scharf MB. Effect of zolpidem on sleep in women with perimenopausal and postmenopausal insomnia: a 4-week, randomized, multicenter, double-blind, placebo-controlled study. Clin Ther 2004;26(10):1578-86
- Teegarden BR, Al Shamma H, Xiong Y. 5HT-2A Inverse-Agonists for the treatment of insomnia. Curr Top Med Chem 2008;8:969-76
- Walsh JK, Thacker S, Knowles LJ, et al. The partial positive allosteric GABAA receptor modulator EVT201 is efficacious and safe in the treatment of adult primary insomnia patients. Sleep Med 2009. [Epub ahead of print]
- Press release, October 16, 2007. Evotec. Available from: http://www.evotec.com/ en/news_events/news_article.aspx? news_id=1160155&news_year=2007&news_month=10
- Press Release, December 13, 2007. Available from: http://www.drugs.com/nda/indiplon_071213.html.
- Neurocrine biosciences; Additional pipeline programs. Available from: http://www.neurocrine.com
- Scharf MB, Black J, Hull S, et al. Long term nightly treatment with indiplon in adults with primary insomnia: results of a double-blind, placebo-controlled 3-month study. Sleep 2007;30:743-52
- Roth T, Walsh JK, Rogowski R, et al. Efficacy and tolerability of Indiplon (NBI-34060) solution in healthy adults in a model of transient insomnia [abstract]. Sleep 2003;26(Suppl):A87
- Scharf M. Saeftya dn efficiacy of immediate release indiplon (NBI-34060) in elderly patients with insomnia [abstract]. Sleep 2003;26(Suppl):A85
- Walsh JM. Efficacy and tolerability of indiplon in older adults with primary insomnia. Sleep Med 2007;8(7-8):753-9
- Lydiard RB, Lankford DA, Seiden DJ, et al. Efficacy and tolerability of modified-release indiplon in elderly patients with chronic insomnia: results of a 2-week double-blind, placebo-controlled trial. J Clin Sleep Med 2006;2(3):309-15
- Marrs J. Indiplon: a Nonbenzodiazepine sedative-hypnotic for the treatment of insomnia. Ann Pharmacother 2008;42:1070-79
- Press release, Neurogen, Nov 7 2008. Available from: http://neurogen.com/ index.php
- Michelsen S, Sánchez C, Ebert B. Lack of generalisation between the GABAA receptor agonist, gaboxadol, and allosteric modulators of the benzodiazepine binding site in the rat drug discrimination procedure. Psychopharmacology (Berl) 2007;193(1):151-7
- Walsh JK, Deacon S, Dijk DJ, Lundahl J. The selective extrasynaptic GABAA agonist, gaboxadol, improves traditional hypnotic efficacy measures and enhances slow wave activity in a model of transient insomnia. Sleep 2007;30(5):593-602
- Walsh JK, Mayleben D, Guico-Pabia C, et al. Efficacy of the selective extrasynaptic GABA A agonist, gaboxadol, in a model of transient insomnia: a randomized, controlled clinical trial. Sleep Med 2008;9(4):393-402
- Staner L, Eriksson M, Cornette F, et al. Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: a polysomnographic study. Sleep Med 2009;10(6):616-20
- Roth T, Hull SG, Lankford DA, et al. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings. Sleep 2008;31(9):1277-84
- Srinivasan V, Pandi-Perumal SR, Trahkt I, et al. Melatonin and melatonineric drugs on sleep: possible mechanisms of action. Int J Neurosci 2009;119(6):821-46
- Montgomery S. Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agent. Eur Neuropsychopharmachol 2006;16:S633-8
- Rivara S, Mor M, Bedini A, et al. Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. Curr Top Chem 2008;8:954-68
- Birznieks G, Scott C, Baroldi P, et al. Melatonin agonist VEC-162 improves sleep onset and maintenance in a model of transient insomnia [abstract]. Sleep 2007;30:A773
- Available from: http://www.vandapharma.com/development.html [Accessed 23 May 2009]
- Rajaratnam S. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 2009;373(9662):482-91
- Stahl S. Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr 2008;12:1-12
- Available from: http://www.somaxon.com/pages/pc_silenor.htm [Accessed 25 May 2009]
- Available from: http://www.hypnion.com/about/news.htm [Accessed 26 May 2009]
- Available from: http://clinicaltrials.gov/ ct2/show/NCT00784875 [Accessed 26 May 2009]
- Press release, Intracellular Therapies, Match 10, 2009. Available from: http://www.intracellulartherapies.com/investor/2009_3_10.htm
- Abbas A, Roth B. Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin Pharmacother 2008;9(18):3251-9
- Nordstrom AL, Mansson M, Jovanovic H, et al. PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain. Int J Neuropsychopharmacol 2008;11(2):163-71
- Jancin B. Eplivanserin soothes insomnia without next-morning effects. Clin Psychiatry News 2008. Available from: http://www.clinicalpsychiatrynews.com/article/S0270-6644(08)70780-X/fulltext
- Available from: http://en.sanofi-aventis.com/binaries/08-03-18_Cowen_ Slide_EN_tcm28-19536.pdf [Accessed 27 May 2009]
- Luthringer R, Prosser W, Arnal MA, et al. Pharmacokinetic and pharmacodynamic effects of the selective 5HT2A inverse agonist APD125 in healthy adults. Sleep 2006;29:A39
- Rosenberg R, Seiden DJ, Hull SG, et al. APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia. Sleep 2008;31(12):1663-71
- Brisbare-Roch C, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007;13(2):150-5
- Roecker A, Coleman P. Orexin receptor antagonists: medicinal chemistry and therapeutic potential. Curr Top Med Chem 2008;8(11):977-87
- Actelion presentations, World Sleep Congress, Cairns, Australia, September 3-6, 2007
- Russel IJ, Perkins AT, Michalek JE; Oxybate SXB-26 Fibromyalgia Syndrome Study Group. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum 2009;60(1):299-309
- Kuo T, Stowers P, Tortora L, et al. Sodium oxybate and zolpidem in the treatment of chronic insomnia: a randomized, doule-blind, double dummy, placebo controlled 3-arm, parallel group study [abstract]. Sleep 2009;32:A835
- Khojasteh A, Khojasteh A, Thornburg BG, Maher KR. Casopitant: a new warrior in the antiemetic crusade. Expert Opin Pharmacother 2009;10(8):1367-76
- Grunberg SM, Rolski J, Strausz J, et al. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10(6):549-58
- Available from: http:// www.gsk-clinicalstudyregister.com/protocol_compounds.jsp [Accessed 23 May 2009]
- Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006;59(11):1052-60